Research Article
Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration
Table 4
Clinical characters, treatments, and outcomes of individual cases analyzed in this study.
| | Baseline | | | | | | During PPV | | Before PPV | | | | | | After PPV | | | | | | | Final condition | BCVA | | | | | Case | Gender | Age (Y) | Onset-PPV (day) | CNV subtype | SMHGD (DD) | Cataract surgery | tPA anti-VEGF | Anti-VEGF | IV (times) | Method | Other treatments | Initial treatment to PPV (M) | Anti-VEGF interval (M) | Anti-VEGF | PPV to IV (M) | IV (times) | Method | Other treatments | PPV to final (M) | Anti-VEGF interval (M) | Macula dry or wet | Before (decimal) | After 1 month | Final | Before-final (log MAR) |
| | SMH | | | | | | | | | | | | | | | | | | | | | | | | | | | 1 | F | 70 | 13 | PCV | 4.1 | PEAIOL | tPA + IVB | — | — | — | — | — | — | IVA | 2 | 10 | LD1PRN→TAE→Fix3M | — | 24 | 2.40 | ΔduringTAE | 0.07 | 0.2 | 0.4 | 0.76 | | 2 | M | 75 | 6 | tAMD | 3.5 | PEAIOL | tPA | — | — | — | — | — | — | IVA | 7 | 7 | LD1PRN→Fix3M→TAE | PPV (MH) | 32 | 4.57 | ΔduringTAE | 0.05 | 0.3 | 0.2 | 0.60 | | 3 | M | 83 | 4 | PCV | 3.1 | PEAIOL | tPA | IVA | 3 | LD3PRN | — | 40 | 13.33 | IVA | 2 | 6 | LDITAE3M→PRN | — | 28 | 4.67 | 〇 | 0.03 | 0.4 | 0.1 | 0.52 | | 4 | M | 64 | 4 | PCV | 2.5 | PEAIOL | tPA | — | — | — | — | — | — | IVA | 1 | 15 | LD3PRN | — | 38 | 2.56 | × | 0.4 | 0.12 | 1 | 0.40 | | 5 | M | 76 | 12 | PCV | 4.3 | PEAIOL | tPA + IVB | — | — | — | — | — | — | IVA | 2 | 12 | LDITAE | — | 28 | 2.33 | × | 0.5 | 0.6 | 0.6 | 0.08 | | 6 | F | 85 | 17 | PCV | 2.0 | PEAIOL | tPA | — | — | — | — | — | — | — | — | — | — | — | 35 | — | ◎ | 0.01 | 0.04 | 0.01 | 0.00 | | 7 | F | 48 | 9 | PCV | 5.7 | Lens preservation | tPA + IVB | — | — | — | — | — | — | — | — | — | — | — | 30 | — | ◎ | 0.7 | 0.5 | 0.4 | −0.24 | | 8 | F | 89 | 9 | PCV | 6.7 | Already IOL | tPA | IVR IVA | 9 | LD1PRN | — | 25 | 2.78 | IVA | 25 | 1 | LD1PRN | PPV (PVR) | 45 | 45 | 〇 | 0.15 | 0.1 | 0.02 | −0.88 |
| | VH | | | | | | | | | | | | | | | | | | | | | | | | | | | 9 | F | 72 | 14 | PCV | — | PEAIOL | — | — | — | — | — | — | — | IVA | 5 | 3 | LD1PRN | PDT before anti-VEGF | 65 | 21.67 | 〇 | 0.01 | 0.6 | 1.2 | 2.08 | | 10 | F | 89 | 53 | PCV | — | Already IOL | — | — | — | — | PDT | 49 | — | — | — | — | — | — | 50 | — | ◎ | LP (+) | 0.3 | 0.15 | 1.88 | | 11 | M | 78 | 62 | PCV | — | Already IOL | IVB | IVA | Unknown | Unknown | — | Unknown | — | — | — | — | — | PC | 36 | — | ◎ | HM | CF | 0.6 | 1.63 | | 12 | M | 74 | 39 | PCV | — | PEAIOL | IVB | — | — | — | — | — | — | — | — | — | — | — | 96 | — | ◎ | LP (+) | 0.02 | 0.02 | 1.00 | | 13 | M | 68 | 24 | tAMD | — | PEAIOL | tPA | IVR IVA | 3 | LD3PRN | — | 24 | 8.00 | — | — | — | — | PPV (VH), PPV + SB (RD) | 29 | — | ◎ | CF | 0.06 | 0.1 | 0.85 | | 14 | M | 81 | 21 | PCV | — | PEAIOL | tPA | IVA | 3 | LD3PRN | — | 6 | 2.00 | IVA | 1 | 8 | LD1PRN | PDT × 3 after anti-VEGF | 37 | 4.68 | Δrest SMH | 0.01 | 0.15 | 0.05 | 0.70 | | 15 | M | 83 | 102 | RAP | — | Already IOL | — | IVB | 1 | LD1PRN | — | 4 | 4.00 | — | — | — | — | — | 76 | — | ◎ | 0.01 | 0.02 | 0.04 | 0.60 | | 16 | M | 86 | 19 | PCV | — | PEAIOL | — | — | — | — | — | — | — | IVA | 32 | 1 | LD1PRN | — | 32 | 32.00 | × | 0.12 | 0.6 | 0.4 | 0.52 | | 17 | M | 67 | 18 | PCV | — | PEAIOL | — | — | — | — | PDT | 28 | — | IVR | 10 | 8 | LD1PRN | PDT after anti-VEGF | 73 | 9.13 | 〇 | 0.04 | 0.1 | 0.1 | 0.40 | | 18 | F | 79 | Unknown | PCV | — | PEAIOL | — | IVR | Unknown | Unknown | PDT | Unknown | — | IVA | 9 | 5 | LD1PRN | PC | 52 | 10.40 | × | LP (+) | 0.01 | HM | 0.40 | | 19 | M | 82 | 75 | PCV | — | Already IOL | tPA + IVB | — | — | — | — | — | — | — | — | — | — | — | 28 | — | ◎ | HM | 0.02 | 0.01 | 0.30 | | 20 | M | 83 | Unknown | RAP | — | Already IOL | — | IVR | 4 | LD3PRN | — | 28 | 7.00 | — | — | — | — | — | 84 | — | ◎ | HM | 0.03 | 0.01 | 0.28 | | 21 | M | 75 | 15 | tAMD | — | PEAIOL | tPA | — | — | — | PC | Unknown | — | — | — | — | — | PPV (SOremove) | 69 | — | ◎ | 0.08 | 0.03 | 0.15 | 0.27 | | 22 | F | 82 | 13 | PCV | — | PEAIOL | — | — | — | — | — | — | — | — | — | — | — | PC | 65 | — | ◎ | 0.6 | 1.2 | 1 | 0.22 | | 23 | M | 67 | 142 | tAMD | — | PEAIOL | — | IVA | 16 | LD3PRN | — | 27 | 1.69 | IVA | 1 | 8 | LD1PRN→Fix3-4M | — | 25 | 3.13 | × | 0.02 | CF | HM | −0.59 | | 24 | M | 67 | Unknown | PCV | — | PEAIOL | tPA | IVA | 6 | LD3PRN | — | 7 | 1.17 | IVA | 1 | 2 | LDIPRN | — | 44 | 22.00 | 〇 | 0.04 | 0.05 | 0.01 | -0.60 | | 25 | F | 80 | Unknown | tAMD | — | Already IOL | — | — | — | — | — | — | — | — | — | — | — | — | 51 | — | ΔSO + SMH | CF | CF | LP (−) | −1.15 |
|
|
PPV: pars plana vitrectomy; BCVA: best-corrected visual acuity; Y: year; CNV: choroidal neovascularization; SMH: submacular hemorrhage; GD: greatest diameter; DD: disc diameter; tPA: tissue plasminogen activator; VEGF: vascular endothelial growth factor; IV: intravitreal injection; M: months; logMAR: logarithm of minimal angle resolution; VH: vitreous hemorrhage; F: female; M: male; PCV: polypoidal choroidal vasculopathy; tAMD: typical age-related macular degeneration; RAP: retinal angiomatous proliferation; IVB: intravitreal bevacizumab; SO: silicone oil; IVA: intravitreal aflibercept; IVR: intravitreal ranibizumab; LD: loading dose; PRN: pro le nata; TAE: treat and extend; MH: macular hole; PVR: proliferative vitreous retinopathy; PDT: photodynamic therapy; PC: photocoagulation; SB: scleral buckling; RD: retinal detachment; ME: macular edema; LP: light perception; HM: hand motion; CF: counting finger. Condition at final follow-up: ◎: dry macula without anti-VEGF after PPV; 〇: dry macula after anti-VEGF discontinued because of reduced activity, △: no fluid but proactive treatment ongoing or wet but anti-VEGF discontinued because of no additional benefit, ×: wet and anti-VEGF therapy ongoing.
|
